Your browser is no longer supported. Please, upgrade your browser.
Settings
VSAR Versartis, Inc. daily Stock Chart
VSAR [NASD]
Versartis, Inc.
Index- P/E- EPS (ttm)-3.45 Insider Own1.50% Shs Outstand37.00M Perf Week1.85%
Market Cap101.75M Forward P/E- EPS next Y-2.52 Insider Trans-79.44% Shs Float33.24M Perf Month-87.41%
Income-115.80M PEG- EPS next Q-0.71 Inst Own72.40% Short Float7.37% Perf Quarter-84.93%
Sales- P/S- EPS this Y-9.70% Inst Trans-22.35% Short Ratio1.34 Perf Half Y-86.08%
Book/sh2.69 P/B1.02 EPS next Y30.20% ROA-63.60% Target Price5.50 Perf Year-76.69%
Cash/sh3.88 P/C0.71 EPS next 5Y- ROE-95.80% 52W Range2.35 - 24.00 Perf YTD-81.54%
Dividend- P/FCF- EPS past 5Y-58.80% ROI- 52W High-88.54% Beta2.44
Dividend %- Quick Ratio2.40 Sales past 5Y- Gross Margin- 52W Low17.02% ATR0.89
Employees71 Current Ratio2.40 Sales Q/Q- Oper. Margin- RSI (14)26.43 Volatility4.38% 8.96%
OptionableYes Debt/Eq0.09 EPS Q/Q-38.20% Profit Margin- Rel Volume1.55 Prev Close2.58
ShortableNo LT Debt/Eq0.09 EarningsNov 02 AMC Payout- Avg Volume1.84M Price2.75
Recom2.80 SMA20-22.62% SMA50-78.14% SMA200-83.31% Volume2,846,381 Change6.80%
Sep-25-17Downgrade Citigroup Buy → Neutral
Sep-22-17Downgrade SunTrust Buy → Hold
Sep-22-17Downgrade Piper Jaffray Overweight → Neutral
Sep-22-17Downgrade Barclays Overweight → Equal Weight $28 → $4
May-05-17Initiated Cantor Fitzgerald Overweight $34
Mar-09-17Initiated Barclays Overweight $28
Dec-20-16Upgrade Credit Suisse Neutral → Outperform
Dec-02-16Initiated SunTrust Buy $25
Oct-04-16Initiated Piper Jaffray Overweight
Dec-17-15Downgrade Credit Suisse Neutral → Underperform
Aug-20-15Initiated Credit Suisse Neutral
Aug-13-15Initiated Morgan Stanley Equal-Weight $17
Jul-07-15Reiterated Canaccord Genuity Buy $20 → $28
Apr-14-15Initiated Sun Trust Rbsn Humphrey Buy $50
Apr-15-14Initiated Canaccord Genuity Buy $36
Sep-25-17 04:04PM  Kroger, Versartis Locked in Mondays 52-Week Low Club 24/7 Wall St. -8.41%
12:54PM  Company News For Sep 25, 2017 Zacks
08:20AM  Today's Research Reports on Stocks to Watch: Exelixis and Versartis ACCESSWIRE
Sep-24-17 10:15AM  Ascendis Pharma shares surge 42% as competitor Versartis plummets 85% on failed trial MarketWatch
Sep-22-17 04:30PM  Why Versartis, Wayfair, and Compass Minerals Slumped Today Motley Fool -87.62%
04:04PM  Versartis, Intercept Pharma Plunge into Fridays 52-Week Low Club 24/7 Wall St.
02:44PM  This Trial Failure Dropped Versartis Inc 86.6% and Lifted Ascendis Pharma 51.4% Motley Fool
12:13PM  Intercept Sinks on Safety Issue, One Analyst Says Buy Anyway - Biotech Movers TheStreet.com
10:45AM  Is This the Death of Versartis? 24/7 Wall St.
10:42AM  T-Mobile, Sprint merger reportedly near, HPE to cut jobs, Finish Line falls Yahoo Finance
10:40AM  T-Mobile, Sprint merger reportedly closer, HPE to cut jobs, Finish Line falls Yahoo Finance Video
08:49AM  Overly complacent investors may be in for a rude Fed wake-up call MarketWatch
08:48AM  Markets brush off North Korea threat Yahoo Finance
08:45AM  Ascendis Pharma shares surge 42% on competitor's flop MarketWatch
07:33AM  Human Growth Drug Flop Sends This Biotech Crashing 83% Investor's Business Daily
Sep-21-17 09:24PM  Is Versartis Inc (VSAR) Undervalued? Simply Wall St.
05:59PM  Versartis growth hormone drug fails key study, shares sink Reuters
05:04PM  Versartis shares down 82% MarketWatch
04:30PM  Versartis Announces Phase 3 VELOCITY Trial of Somavaratan in Pediatric Growth Hormone Deficiency Did Not Meet Primary Endpoint GlobeNewswire
08:44AM  Versartis, Inc. (VSAR) in Focus: Stock Moves 11.5% Higher Zacks
Sep-18-17 08:35AM  Implied Volatility Surging for Versartis (VSAR) Stock Options Zacks +6.27%
Sep-07-17 04:05PM  Versartis Twice-Monthly Somavaratan for Pediatric Growth Hormone Deficiency to be Featured in Oral and Poster Presentations at IMPE 2017 GlobeNewswire +7.44%
Sep-05-17 04:05PM  Versartis Announces Expansion of Executive Leadership Team with Addition of Dr. Robert Gut as the Head of Global Clinical, Medical and Regulatory Affairs GlobeNewswire
Aug-31-17 08:50AM  Implied Volatility Surging for Versartis (VSAR) Stock Options Zacks
Aug-03-17 08:38AM  Options Traders Expect Huge Moves in Versartis (VSAR) Stock Zacks
Aug-02-17 08:30AM  Versartis to Present at the Canaccord Genuity Growth Conference GlobeNewswire
Jul-28-17 08:05PM  Versartis reports 2Q loss Associated Press
Jul-27-17 04:05PM  Versartis Reports Second Quarter 2017 Financial Results GlobeNewswire
Jun-21-17 08:52AM  Is the Options Market Predicting a Spike in Versartis (VSAR) Stock? Zacks +5.28%
Jun-01-17 08:30AM  Versartis Appoints Eric Dobmeier to Board of Directors GlobeNewswire +6.51%
May-26-17 12:09PM  INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Versartis Inc. Business Wire
May-22-17 08:15AM  Versartis Presents 3-Year Somavaratan Safety and Efficacy Data and Pediatric Program Baseline Demographics at the 19th European Congress of Endocrinology GlobeNewswire
Apr-27-17 06:04PM  Versartis reports 1Q loss Associated Press
04:05PM  Versartis Reports First Quarter 2017 Financial Results GlobeNewswire
Apr-26-17 11:42AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Versartis Inc. - VSAR Accesswire
Apr-25-17 08:30AM  Versartis Appoints Jay Stout, Ph.D., as Senior Vice President, Technical Operations GlobeNewswire
Apr-03-17 11:32AM  VERSARTIS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
11:20AM  Versartis Announces Three Year Somavaratan Data at ENDO 2017 Showing Safety and Efficacy in Line with Historical U.S. Daily rhGH Data in Pediatric GHD PR Newswire
07:30AM  Versartis Reports New Data on Long-Acting Somavaratan in Growth Hormone Deficiency at ENDO 2017 PR Newswire
Mar-30-17 04:56PM  Insider Invests in Versartis
Mar-23-17 04:22PM  VERSARTIS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obliga
08:30AM  Versartis to Host Conference Call to Review Data from ENDO 2017 on Long-Acting Somavaratan for Growth Hormone Deficiency GlobeNewswire
Mar-22-17 09:30AM  Rennova Health and Versartis Have Different Reasons for Optimism Accesswire
Mar-21-17 10:25AM  5 Biotech Stocks That Could Skyrocket From Upcoming Catalysts 24/7 Wall St.
Mar-16-17 01:04PM  VERSARTIS, INC. Financials
Mar-15-17 08:30AM  Versartis Appoints Tracy Woody as Chief Commercial Officer GlobeNewswire
Mar-10-17 07:17AM  VERSARTIS, INC. Files SEC form 10-K, Annual Report
Mar-09-17 12:27PM  Coverage initiated on Versartis by Barclays
09:14AM  Barclays Sees 40% Upside In Versartis Over Next Year Benzinga
Mar-02-17 08:30AM  Versartis Announces Data on Long-Acting Somavaratan for Growth Hormone Deficiency to be Featured in Late-Breaker Presentation at ENDO 2017 GlobeNewswire
Mar-01-17 04:36PM  Versartis to Present at Cowen & Co. Annual Healthcare Conference and Barclays Global Healthcare Conference GlobeNewswire
Feb-25-17 12:26AM  [$$] The Length of a Biotech Patent's Life, Corrected at Barrons.com
Feb-23-17 06:00AM  These Small Biotechs Are Poised to Go Higher at Investopedia +8.21%
Feb-21-17 04:51PM  Versartis reports 4Q loss +15.90%
04:31PM  VERSARTIS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:05PM  Versartis Reports Fourth Quarter 2016 Financial Results GlobeNewswire
Feb-18-17 01:26AM  [$$] Why Biotech Looks Like a Good Bet in 2017 at Barrons.com
Feb-15-17 02:04PM  Twitter Is One of Five Stocks Insiders Really Love Right Now
Jan-31-17 05:02PM  VERSARTIS, INC. Files SEC form 8-K, Change in Directors or Principal Officers +10.00%
08:30AM  Versartis Promotes Joshua T. Brumm to Chief Operating Officer and Paul Westberg to Chief Business Officer GlobeNewswire
Jan-30-17 06:56PM  Versartis Long-Acting Somavaratan for Growth Hormone Deficiency to be Featured in Multiple Oral and Poster Presentations at ENDO 2017 GlobeNewswire -9.09%
Jan-13-17 11:00AM  Versartis' Pipeline Holds Big Promise
Jan-09-17 08:40AM  Adamas Pharmaceuticals (ADMS) in Focus: Stock Up 5.4%
Jan-08-17 10:10AM  Huge Energy Trade Kicks Off 2017 Insider Buying: DCP Midstream, Och-Ziff Capital, TransEnterix, Amicus Therapeutics and More
Jan-05-17 08:20AM  Versartis (VSAR) Shares March Higher, Can It Continue?
Jan-04-17 02:47PM  5 Stocks Insiders Are Loading Up On +7.38%
Dec-28-16 04:32PM  VERSARTIS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
Dec-04-16 03:56PM  150% Surge in Smart Money Ownership of Versartis Inc (VSAR): What Have They Discovered? at Insider Monkey
Nov-29-16 12:41PM  VERSARTIS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Nov-28-16 02:23PM  Versartis, Inc. :VSAR-US: Earnings Analysis: Q3, 2016 By the Numbers : November 28, 2016 -5.97%
Nov-07-16 07:30AM  Versartis Presents Safety, Efficacy and IGF-I Data for Somavaratan in Pediatric Growth Hormone Deficiency at the 2016 Congress of the GRS & IGF Society GlobeNewswire +6.04%
Nov-04-16 05:19PM  VERSARTIS, INC. Files SEC form 10-Q, Quarterly Report
Nov-03-16 06:48PM  Versartis reports 3Q loss -5.56%
04:12PM  VERSARTIS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:05PM  Versartis Reports Third Quarter 2016 Financial Results GlobeNewswire
Oct-31-16 08:30AM  Versartis to Present at Two Investor Conferences in November GlobeNewswire -9.80%
Oct-17-16 09:00AM  Phase 3 Enrollment Initiated in Japan for Versartis' Long-Acting Growth Hormone Based on Amunix's XTEN(R) Technology Marketwired
Oct-14-16 04:20PM  VERSARTIS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Sep-29-16 06:04AM  VERSARTIS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Sep-28-16 03:04PM  Ferrellgas Partners LP (FGP), Real Goods Solar Inc (RGSE) Among Stocks on the Move on Wednesday at Insider Monkey -8.25%
09:02AM  Versartis Announces Pricing of Follow-On Offering GlobeNewswire
Sep-27-16 04:01PM  Versartis Announces Proposed Offering of Common Stock GlobeNewswire
Sep-26-16 07:06AM  VERSARTIS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:00AM  Versartis Initiates Phase 3 Trial of Somavaratan in Japan for Children with Growth Hormone Deficiency Following Completion of Phase 2 GlobeNewswire
Sep-15-16 08:04AM  VERSARTIS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Sep-13-16 03:29PM  Versartis, Inc. :VSAR-US: Earnings Analysis: Q2, 2016 By the Numbers : September 13, 2016 -6.84%
Sep-12-16 09:11AM  VERSARTIS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:30AM  Versartis Presents Data From Up to 30 Months of Somavaratan Treatment for Pediatric Growth Hormone Deficiency at the 2016 ESPE Annual Meeting GlobeNewswire
Sep-06-16 08:35AM  Versartis to Present at the Morgan Stanley Global Healthcare Conference GlobeNewswire
08:30AM  Versartis to Host Investor Symposium Featuring Leading Experts in Growth Hormone Deficiency GlobeNewswire
Sep-02-16 04:18PM  VERSARTIS, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits -5.10%
04:05PM  Versartis Presents Efficacy, Safety, Metabolic and Adherence Data for Somavaratan in Oral Session at the International Congress of Endocrinology GlobeNewswire
Sep-01-16 03:00AM  Long Acting Growth Hormone Based on Amunix' XTEN(R) Technology Completes Enrollment of Phase 3 Trial Marketwired +6.05%
Aug-22-16 08:30AM  Versartis Announces Completion of Enrollment in Phase 3 VELOCITY Trial of Somavaratan in Pediatric GHD GlobeNewswire
Aug-09-16 04:08PM  VERSARTIS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
04:05PM  Teijin Limited and Versartis Enter Strategic Alliance for Commercialization of Somavaratan Long-Acting Growth Hormone in Japan GlobeNewswire
Aug-04-16 08:30AM  Versartis to Present at the Canaccord Genuity 36th Annual Growth Conference GlobeNewswire
Aug-03-16 06:08AM  VERSARTIS, INC. Files SEC form 10-Q, Quarterly Report
Jul-28-16 05:59PM  Versartis reports 2Q loss
04:17PM  VERSARTIS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
Versartis, Inc. operates as an endocrine-focused biopharmaceutical company in the United States. The company is developing VRS-317, a long-acting recombinant human growth hormone, which is in Phase III clinical trials for the treatment of growth hormone deficiency. It develops drug candidates that it has licensed from Amunix Operating, Inc. The company was founded in 2008 and is headquartered in Menlo Park, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PERCEPTIVE ADVISORS LLC10% OwnerSep 22Sale3.201,650,0005,281,7502,099,563Sep 25 04:07 PM
PERCEPTIVE ADVISORS LLC10% OwnerSep 21Sale3.61480,0001,731,8023,749,563Sep 25 04:07 PM
Westberg PaulSVP and Chief Business OfficerJun 13Sale16.0571111,41267,517Jun 14 06:51 PM
Brumm Joshua TCOO and CFOJun 13Sale16.051,42122,807105,595Jun 14 06:50 PM
Brumm Joshua TCOO and CFOMay 16Sale17.401,26321,976107,016May 17 06:29 PM
Shepard JayPresident and CEOMay 11Sale17.509,114159,495204,744May 15 05:02 PM
Westberg PaulSVP and Chief Business OfficerApr 19Sale19.851,31626,12368,228Apr 20 05:23 PM
Hislop ColinChief Medical OfficerApr 04Option Exercise8.1735,000285,95059,500Apr 05 07:02 PM
Hislop ColinChief Medical OfficerApr 04Sale21.2035,000742,00024,500Apr 05 07:02 PM
AKKARAJU SRINIVASDirectorMar 24Buy12.25571,4297,000,005571,429Mar 28 08:06 PM
Malik ShahzadDirectorMar 17Sale18.01386,3676,958,4701,621,558Mar 17 05:29 PM
Malik ShahzadDirectorMar 16Sale18.5097,3031,800,1062,007,925Mar 17 05:29 PM
Malik ShahzadDirectorMar 15Sale19.08103,1221,967,5682,105,228Mar 15 05:44 PM
Ward ShaneSVP and General CounselMar 15Sale19.0277614,76036,350Mar 15 05:31 PM
Ward ShaneSVP and General CounselMar 14Sale19.001,26524,03537,126Mar 15 05:31 PM
Malik ShahzadDirectorMar 14Sale19.0046,878890,6852,208,350Mar 15 05:44 PM
Malik ShahzadDirectorMar 13Sale19.4216,330317,1292,255,228Mar 15 05:44 PM
Westberg PaulSVP and Chief Business OfficerFeb 27Option Exercise1.9812,50024,71782,044Feb 28 07:36 PM
Shepard JayPresident and CEOFeb 27Option Exercise2.535,16613,070219,024Feb 28 07:34 PM
Shepard JayPresident and CEOFeb 27Sale24.005,166123,984213,858Feb 28 07:34 PM
Westberg PaulSVP and Chief Business OfficerFeb 27Sale22.5012,500281,25069,544Feb 28 07:36 PM
Brumm Joshua TCOO and CFOFeb 24Option Exercise2.5330,00075,900135,779Feb 28 07:33 PM
Brumm Joshua TCOO and CFOFeb 24Sale20.9430,000628,063105,779Feb 28 07:33 PM
Shepard JayPresident and CEOFeb 23Option Exercise2.538,00020,240221,858Feb 23 08:23 PM
Westberg PaulSVP and Chief Business OfficerFeb 23Option Exercise1.616,59010,61076,134Feb 23 08:25 PM
Westberg PaulSVP and Chief Business OfficerFeb 23Sale20.006,590131,80069,544Feb 23 08:25 PM
Shepard JayPresident and CEOFeb 23Sale20.008,000160,000213,858Feb 23 08:23 PM
Shepard JayPresident and CEOFeb 21Option Exercise2.538,00020,240221,858Feb 23 08:23 PM
Westberg PaulSVP and Chief Business OfficerFeb 21Option Exercise1.6118,41029,64087,954Feb 23 08:25 PM
Westberg PaulSVP and Chief Business OfficerFeb 21Sale18.3018,410336,95069,544Feb 23 08:25 PM
Shepard JayPresident and CEOFeb 21Sale18.508,000148,000213,858Feb 23 08:23 PM
PERCEPTIVE ADVISORS LLC10% OwnerFeb 13Buy15.5159,133917,4254,228,563Feb 14 08:45 AM
PERCEPTIVE ADVISORS LLC10% OwnerFeb 10Buy14.9434,883521,2814,169,430Feb 14 08:45 AM
PERCEPTIVE ADVISORS LLC10% OwnerFeb 09Buy14.2741,211587,9284,134,547Feb 10 08:45 AM
PERCEPTIVE ADVISORS LLC10% OwnerFeb 08Buy13.51104,6121,413,3194,093,336Feb 10 08:45 AM
Shepard JayPresident and CEOFeb 03Sale13.696,71991,983213,858Feb 06 05:23 PM
Shepard JayPresident and CEOFeb 02Option Exercise2.534,16610,540227,550Feb 02 08:12 PM
Shepard JayPresident and CEOFeb 02Sale13.516,97394,205220,577Feb 02 08:12 PM
Shepard JayPresident and CEOFeb 01Option Exercise2.536,57616,637229,960Feb 02 08:12 PM
Shepard JayPresident and CEOFeb 01Sale13.956,57691,735223,384Feb 02 08:12 PM
Shepard JayPresident and CEOJan 31Option Exercise2.5310,66226,975234,046Feb 02 08:12 PM
Shepard JayPresident and CEOJan 31Sale13.8210,662147,385223,384Feb 02 08:12 PM
Shepard JayPresident and CEOJan 30Option Exercise2.5310,59626,808233,980Jan 31 08:34 PM
Brumm Joshua TCOO and CFOJan 30Sale13.852,94540,794105,779Jan 31 08:36 PM
Shepard JayPresident and CEOJan 30Sale13.5217,270233,468223,384Jan 31 08:34 PM
Ward ShaneSVP and General CounselJan 30Sale13.851,47420,41838,391Jan 31 08:31 PM
Westberg PaulSVP and Chief Business OfficerJan 30Sale13.851,91626,54069,544Jan 31 08:29 PM
Westberg PaulSr. VP, Corporate DevelopmentJan 11Option Exercise1.617,93112,76952,531Jan 11 09:21 PM
Westberg PaulSr. VP, Corporate DevelopmentJan 11Sale15.247,931120,86844,600Jan 11 09:21 PM
Westberg PaulSr. VP, Corporate DevelopmentJan 10Option Exercise1.4011,21315,64655,813Jan 11 09:21 PM
Westberg PaulSr. VP, Corporate DevelopmentJan 10Sale15.6611,213175,59644,600Jan 11 09:21 PM
Westberg PaulSr. VP, Corporate DevelopmentJan 09Option Exercise1.3613,35618,16557,956Jan 11 09:21 PM
Westberg PaulSr. VP, Corporate DevelopmentJan 09Sale15.9313,356212,76144,600Jan 11 09:21 PM
PERCEPTIVE ADVISORS LLC10% OwnerDec 30Buy14.6694,7501,388,8464,013,411Jan 04 02:26 PM
PERCEPTIVE ADVISORS LLC10% OwnerDec 29Buy14.3747,375680,5893,918,661Dec 30 08:46 AM
Westberg PaulSr. VP, Corporate DevelopmentDec 27Sale15.853615,72244,600Dec 29 06:19 PM
Brumm Joshua TChief Financial OfficerDec 27Sale15.8599015,69264,824Dec 29 06:15 PM
Westberg PaulSr. VP, Corporate DevelopmentDec 16Option Exercise1.275,0006,32549,961Dec 19 07:37 PM
Westberg PaulSr. VP, Corporate DevelopmentDec 16Sale15.005,00075,00044,961Dec 19 07:37 PM
JENNINGS EDMON RDirectorDec 08Sale12.961,50019,4337,700Dec 08 09:10 PM
Brumm Joshua TChief Financial OfficerDec 07Sale13.253,02140,02865,814Dec 08 05:18 PM